Latest Lead News

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

ABx Group’s mixed rare earth carbonate from Tasmania’s Deep Leads project has earned strong validation from US-based Rare Earth Technologies Inc, confirming its high purity and compatibility with cutting-edge separation technology.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

Chariot Resources has raised A$2.1 million through a share placement, attracting institutional and sophisticated investors to back its expanding lithium projects in the US and Nigeria. The placement includes free attaching options, pending shareholder approval.

Advanced Energy Minerals is ramping up production capacity at its Quebec plant, leveraging patented low-cost technology and renewable energy to meet booming global demand for high purity alumina.

Atlantic Lithium secures a crucial green light from Ghana’s Parliament for its Ewoyaa Lithium Project, marking a key step towards production and investment decisions.

Theta Gold Mines has locked in a key manufacturing contract for its TGME Gold Project, securing critical equipment that keeps the project on track for commissioning in late 2026 and first gold production early next year.

Vintage Energy has launched a $2.1 million equity entitlement offer to fund drilling two new gas wells, supported by a South Australian government grant, and to advance oil exploration in the Cooper Basin.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Ramelius Resources has withdrawn forward-looking financial statements based on a high gold price assumption, issuing a revised investor presentation that reaffirms its strong production growth and shareholder return plans through to FY30.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

TMK Energy has raised $6 million in a heavily oversubscribed placement led by coal seam gas experts, aiming to accelerate drilling and commercialisation at its Gurvantes XXXV project.